Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV

127Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

T-1249 is a 39-aa synthetic peptide that inhibits fusion of human immunodeficiency virus (HIV) to the host target cell. A 14-day open-label, phase 1/2 dose-escalation monotherapy study of the safety and antiretroviral activity of T-1249 was performed on 115 HIV-1-infected adults. At baseline, the majority of the patients had advanced HIV disease (baseline median CD4 + cell count, 57 cells/μL) and had extensive pretreatment (i.e., pre-T-1249) experience with antiretroviral medications (median, 11 antiretroviral drugs). Patients received T-1249 monotherapy by subcutaneous injection, for 14 days, at doses ranging from 6.25 to 192 mg/day. T-1249 was generally well tolerated, and no dose-limiting toxicity was identified. Injection-site reactions were the most commonly reported adverse event (57%). Dose-dependent decreases in plasma HIV-1 RNA load were observed; the median maximum change from baseline across dose groups ranged from -0.29 log 10 copies/mL (95% confidence interval [CI], -0.43 to -0.05 log 10 copies/mL) for the lowest dose to -1.96 log10 copies/ mL (95% CI, -2.02 to -1.37 copies/mL) for the highest dose. These results indicate that T-1249 is a potent new therapeutic agent for HIV-1 infection.

Cite

CITATION STYLE

APA

Eron, J. J., Gulick, R. M., Bartlett, J. A., Merigan, T., Arduino, R., Kilby, J. M., … Miralles, G. D. (2004). Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. Journal of Infectious Diseases, 189(6), 1075–1083. https://doi.org/10.1086/381707

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free